论文部分内容阅读
Two patients with myasthenia gravis (Ossermann IIb) involving invasive thymoma who underwent extensive thymectomy manifested myasthenic crisis shortly after t he procedure; however,both patients were treated with intravenous immunoglobulin and recovered from myasthenic crisis that had been deteriorating for about 1 we ek. Subsequently, the patients were administered a low-dose of tacrolimus (3 mg /day) in addition to prednisolone. Several months later, tacrolimus continued tocontrol fluctuations of myasthenic sympto ms and maintained remission in these patients.The serum titer of anti-Ach-rece ptor antibodies decreased in parallel with clinical improvement due to tacrolimu s,and we accordingly reduced the dosage of prednisolone.Tacrolimus is a new immu nosuppressive agent acting through the selective inhibition of helper-T-cell a ctivation that can be reduced dosage of steroids and can maintainremission of my asthenia gravis with invasive thymoma.
Two patients with myasthenia gravis (Ossermann IIb) involving invasive thymoma who underwent extensive thymectomy manifested myasthenic crisis shortly after t he procedure; however, both patients were treated with intravenous immunoglobulin and recovered from myasthenic crisis that had been deteriorating for about 1 we ek. , the patients were administered a low-dose of tacrolimus (3 mg / day) in addition to prednisolone. Several months later, tacrolimus continued tocontrol fluctuations of myasthenic sympto ms and maintained remission in these patients. serum titer of anti-Ach-rece ptor antibodies decreased in parallel with clinical improvement due to tacrolimus, and we compared reduced the dosage of prednisolone. Tacrolimus is a new immu nosuppressive agent acting through the selective inhibition of helper-T-cell a ctivation that can be reduced dosage of steroids and can maintainremission of my asthenia gravis with invasive thymoma.